Iacovoni Attilio, D'Elia Emilia, Gori Mauro, Oliva Fabrizio, Lorini Ferdinando Luca, Senni Michele
Cardiovascular Department, ASST Papa Giovanni XXIII Bergamo, Italy.
Cardiovascular Department, ASST Grande Ospedale Metropolitano Niguarda Milan, Italy.
Card Fail Rev. 2019 May 24;5(2):78-82. doi: 10.15420/cfr.2018.46.2. eCollection 2019 May.
Heart failure (HF) is a pandemic syndrome characterised by raised morbidity and mortality. An acute HF event requiring hospitalisation is associated with a poor prognosis, in both the short and the long term. Moreover, early rehospitalisation after discharge negatively affects HF management and survival rates. Cardiovascular and non-cardiovascular conditions combine to increase rates of HF hospital readmission at 30 days. A tailored approach for HF pharmacotherapy while the patient is in hospital and immediately after discharge could be useful in reducing early adverse events that cause rehospitalisation and, consequently, prevent worsening HF and readmission during the vulnerable phase after discharge.
心力衰竭(HF)是一种发病率和死亡率都很高的大流行综合征。需要住院治疗的急性HF事件在短期和长期内都与不良预后相关。此外,出院后早期再次住院会对HF的管理和生存率产生负面影响。心血管和非心血管疾病共同导致HF患者30天内再次入院率增加。在患者住院期间和出院后立即采用量身定制的HF药物治疗方法,可能有助于减少导致再次住院的早期不良事件,从而防止在出院后的脆弱阶段HF病情恶化和再次入院。